A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Combining radiotherapy with PD1 blockade has had impressive antitumor effects in preclinical models of metastatic lung cancer, although anti-PD1 resistance remains problematic. Here, we report results from a triple-combination therapy in which NBTXR3, a clinically approved nanoparticle radioenhancer, is combined with high-dose radiation (HDXRT) to a primary tumor plus low-dose radiation (LDXRT) to a secondary tumor along with checkpoint blockade in a mouse model of anti-PD1-resistant metastatic lung cancer. Methods: Mice were inoculated with 344SQR cells in the right legs on day 0 (primary tumor) and the left legs on day 3 (secondary tumor). Immune checkpoint inhibitors (ICIs), including anti-PD1 (200 μg) and anti-CTLA4 (100 μg) were given intraperitoneally. Primary tumors were injected with NBTXR3 on day 6 and irradiated with 12-Gy (HDXRT) on days 7, 8, and 9; secondary tumors were irradiated with 1-Gy (LDXRT) on days 12 and 13. The survivor mice at day 178 were rechallenged with 344SQR cells and tumor growth monitored thereafter. Results: NBTXR3 + HDXRT + LDXRT + ICIs had significant antitumor effects against both primary and secondary tumors, improving the survival rate from 0 to 50%. Immune profiling of the secondary tumors revealed that NBTXR3 + HDXRT + LDXRT increased CD8 T-cell infiltration and decreased the number of regulatory T (Treg) cells. Finally, none of the re-challenged mice developed tumors, and they had higher percentages of CD4 memory T cells and CD4 and CD8 T cells in both blood and spleen relative to untreated mice. Conclusions: NBTXR3 nanoparticle in combination with radioimmunotherapy significantly improves anti-PD1 resistant lung tumor control via promoting antitumor immune response. Graphical Abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1297 · Cited by 243 · cited 1×
“NBTXR3, which has been approved for the treatment of localized sarcoma [8], increases radiation-mediated damage to cancer cells and promotes activation of the STING pathway [9, 10], both of which could contribute to immune priming.”
Background
Cited by
The artificial intelligence and machine learning in lung cancer immunotherapy
Gao, Q., Yang, L., Lu, M., Jin, R., Ye, H., & Ma, T. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01456-y · Cited by 148
Self-citationApplication of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment
Jackson, N., Cecchi, D., Beckham, W., & Chithrani, D. B. (2024) · Molecules · doi:10.3390/molecules29112438 · Cited by 52
“Additionally, preclinical studies have suggested that NBTXR3 can enhance the efficacy of immunother-apies by bolstering the antitumor immune response, prompting clinical investigations of the combined treatment modalities (NCT05039632, NCT04862455, NCT03589339, and NCT04892173) [100–102].”
BackgroundBienassis, C., Vivar, O. I., Hu, Y., Da silva, J., Darmon, A., Marill, J., Anesary, N. M., Schmitt, P., Levy, L., Welsh, J., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03579-1 · Cited by 9
“Multiple preclinical studies have shown that the combination of NBTXR3 + RT can impact various pathways associated with antitumor immune activation, boosting the immune system’s capacity to identify and destroy tumor cells [15, 16, 20, 32].”
Self-citation
Metadata
- Authors
- Hu, Y., Paris, S., Barsoumian, H., Abana, C. O., He, K., Sezen, D., Wasley, M., Masrorpour, F., Chen, D., Yang, L., Dunn, J. D., Gandhi, S., Nguyen, Q.-N., Cortez, M. A., & Welsh, J. W.
- Venue
- Journal of Nanobiotechnology
- Published
- 2021-12
- Volume
- 19
- Issue
- 1
- Pages
- 416-416
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W4200611251
- Cited by
- 41
- References
- 1
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. https://app.cochat.ai/papers/10.1186/s12951-021-01163-1
- The paper
- Hu, Y., Paris, S., Barsoumian, H., Abana, C. O., He, K., Sezen, D., Wasley, M., Masrorpour, F., Chen, D., Yang, L., Dunn, J. D., Gandhi, S., Nguyen, Q.-N., Cortez, M. A., & Welsh, J. W. (2021). A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-021-01163-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.